Sitemap
Blog Post
- The FLF announces appointment of its first chief medical officer
- Mike Thompson, Trustee of the FLF, awarded MBE
- Nicky Greenhalgh - Founder of Living with Follicular Lymphoma community
- The Follicular Lymphoma Foundation research goals - patient poll results - September 2021
- "Running the Virgin Money London Marathon" by Emily Watson
- What are clinical trials?
- ASH annual meeting 2021 round-up
- Everything you need to know about Follicular Lymphoma clinical trials
- Blood tests in Follicular Lymphoma
- Kate Rogers appointed as Chief Executive Officer of the Follicular Lymphoma foundation (FLF)
- FLF Newsletter Q1 2022
- Antibody response to CoV-2 vaccines
- Fundraising - thank you Richard
- Thank you Ailsa - for the dance show and your donation
- Kate Rogers our new CEO
- The fabulous kindness of the Snowdown Colliery Welfare Brass Band
- A big thank-you to all at Henry and Esther’s Golden Anniversary celebration
- Our Q3 newsletter
- CURE FL Awards. Funding $2m of targeted, innovative, patient driven research
- FLF are attending the ASH 2022 Annual Meeting
- Research in focus: Bi-specific antibodies approval.
- Engaging the inhibitory BTLA Receptor for the Treatment of Follicular Lymphoma
Hans-Guido Wendel, MD, PhD
Memorial Sloan Kettering Cancer Center - Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL
Patricia Pérez-Galán, PhD,
Institut d’Investigacions Biomèdiques August Pi I Sunyer - Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma
Wendy Béguelin, PhD,
Weill Cornell Medicine - The FLF’s Precision Medicine Programme research goals
- Educational workshop covering targeted therapies for FL
- Enhancing Fas-mediated Bystander Killing of Follicular Lymphoma to prevent post-immunotherapy antigen escape
Joshua Brody, MD,
Icahn School of Medicine at Mount Sinai - Looking back over the last 25 years for FL – the Rituximab era
- ASH Annual Meeting 2022 - Research and insight summary
- Our Q4 newsletter
